JGC
IMNM icon

J. Goldman & Co’s Immunome IMNM Stock Holding History

J. Goldman & Co’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-67,600
Closed -$792K – 639
2025
Q3 		$792K Buy
+67,600
New +$672K 0.02% 351

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

J. Goldman & Co's IMNM Position: Q4 2025 in Review

J. Goldman & Co sold out of Immunome (IMNM) in Q4 2025, closing a stake of 61,344 shares — an estimated $718K sold.

J. Goldman & Co first reported a position in IMNM in Q1 2024 and held it in 3 quarters. The position peaked at $1.93M in Q1 2024. 182 funds tracked by Wall St. Rank hold IMNM as of Q4 2025.

  • J. Goldman & Co reported no remaining Immunome position as of Q4 2025 after selling out during the quarter.
  • J. Goldman & Co sold 61,344 Immunome shares in Q4 2025, an estimated $718K.
  • J. Goldman & Co first reported a position in Immunome in Q1 2024 and held it in 3 quarters.
  • J. Goldman & Co's Immunome position peaked at $1.93M in Q1 2024.
  • 182 funds tracked by Wall St. Rank held Immunome as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.